Table 1 Clinical characteristics and survival in patients with inoperable NSCLC: univariate survival analysis

From: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

 

Patients 161 (100%)

Survival (months) Median (95% CI)

P value

Age

 <60 years

37 (23)

10.3 (8.2–12.4)

 

 ⩾60 years

124 (77)

8.2 (6.1–10.3)

0.593

Sex

 Male

105 (65)

9.1 (6.6–11.6)

 

 Female

56 (35)

8.9 (5.9–11.8)

0.810

Stage

 III

57 (35)

12.0 (8.1–15.9)

 

 IV

104 (65)

6.9 (4.0–9.9)

0.015

Type

 Squamous

64 (40)

9.7 (5.9–13.5)

 

 Adenocarcinoma

53 (33)

9.0 (2.6–15.3)

 

 Other

44 (27)

3.9 (0.2–7.9)

0.003

Performance status (ECOG)

 0–1

91 (57)

12.0 (8.7–15.4)

 

 2–4

70 (43)

4.2 (1.6–6.7)

<0.001

Haemoglobin

 ⩾12 g l−l

101 (63)

9.1 (6.3–11.9)

 

<12 g l−l

60 (37)

8.9 (6.4–11.3)

0.187

White cell count

 ⩽10 × 109 l−l

82 (51)

12.4 (7.9–16.9)

 

>10 × 109 l−1

79 (49)

6.5 (2.9–10.0)

0.003

Albumin

 ⩾35 g l−l

126 (78)

10.1 (7.4–12.8)

 

 <35 g l−l

35 (22)

3.7 (2.3–5.1)

<0.001

C-reactive protein

 ⩽10 mg l−l

29 (18)

16.4 (11.0–21.7)

 

 >10 mg l−l

132 (82)

7.1 (4.9–9.3)

0.003

Treatment

 Active

63 (39)

13.3 (10.4–16.2)

 

 Palliative

98 (61)

4.7 (2.0–7.5)

<0.001

Back to article page